M
Martin C. Müller
Researcher at Heidelberg University
Publications - 179
Citations - 14792
Martin C. Müller is an academic researcher from Heidelberg University. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 54, co-authored 178 publications receiving 13711 citations. Previous affiliations of Martin C. Müller include University Hospital Heidelberg & Medical University of Graz.
Papers
More filters
Journal ArticleDOI
Evaluating The Quality of Selective Emitter Structures by Imaging the Emitter Saturation Current Density
TL;DR: In this paper, a method to derive the emitter saturation current density with lateral resolution is applied to investigate selective emitter structures using PL lifetime imaging at several injection densities to laterally evaluate J0e by applying the method of Kane and Swanson pixel by pixel.
Journal ArticleDOI
Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).
M. Philipp,Juliana Schwaab,Christian Dietz,Benjamin Hanfstein,Lida Kalmanti,U. Munjal,Maximilian Mossner,Daniel Nowak,Wolfgang Seifarth,W.-K. Hofmann,Andreas Hochhaus,Martin C. Müller,Philipp Erben +12 more
TL;DR: TKTL1 expression levels appear to decline in the course of CML with lowest levels during blast crisis, and a potential reason is a shift of TK TL1-high-expressing mature granulocytes towards TKTL 1-low- expressing immature cells and blasts.
Journal ArticleDOI
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study
Helen E. White,M D Salmon,Francesco Albano,Christina Maar Andersen,Stefan Balabanov,Gueorgui Balatzenko,Gisela Barbany,Jean-Michel Cayuela,Nuno Cerveira,Pascale Cochaux,Dolors Colomer,Daniel Coriu,Joana Diamond,Christian Dietz,Stéphanie Dulucq,M. Engvall,Georg-Nikolaus Franke,Egle Gineikiene-Valentine,Michał Gniot,María Teresa Gómez-Casares,Enrico Gottardi,C. Hayden,Sandrine Hayette,Andreas Hedblom,Anca Ilea,Barbara Izzo,Antonio Jiménez-Velasco,Tomáš Jurček,Veli Kairisto,Stephen E. Langabeer,Thomas Lion,Nóra Meggyesi,S. Mesanovic,Ľuboslav Mihók,Gerlinde Mitterbauer-Hohendanner,Sylvia Moeckel,Nicole Naumann,Olivier Nibourel,Elisabeth Oppliger Leibundgut,Panayiotis Panayiotidis,Helena Podgornik,Christiane Pott,I. Rapado,S. Rose,Vivien Schäfer,Tasoula Touloumenidou,Christopher Veigaard,Bianca Venniker-Punt,Claudia Venturi,Paolo Vigneri,Ingvild Vorkinn,E Wilkinson,Renata Zadro,Magdalena Zawada,Hana Zizkova,Martin C. Müller,Susanne Saussele,Thomas Ernst,Katerina Machova Polakova,Andreas Hochhaus,Nicholas C.P. Cross +60 more
TL;DR: In this article , secondary reference panels are used to obtain and validate conversion factors in a manner equivalent to sample exchange and can also be used to monitor additional aspects of quality assurance, such as internal quality control.
Journal ArticleDOI
Comparing the Prognostic Significance of Early Predictors of Survival in Chronic Myeloid Leukemia (CML) Treated with Imatinib - an Analysis of the Randomized CML-Study IV
Benjamin Hanfstein,Michael Lauseker,Rüdiger Hehlmann,Susanne Saussele,Philipp Erben,Christian Dietz,Alice Fabarius,Ulrike Proetel,Lida Kalmanti,Susanne Schnittger,Stefan W. Krause,J. Schubert,Hermann Einsele,Mathias Hänel,Jolanta Dengler,Christiane Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael Pfreundschuh,Cornelius F. Waller,Karsten Spiekermann,Gabriela M. Baerlocher,Markus Pfirrmann,Joerg Hasford,Wolf-Karsten Hofmann,Andreas Hochhaus,Martin C. Müller +28 more
TL;DR: The 10% BCR-ABLIS landmark, which is currently defining treatment failure at 6 months according to European LeukemiaNet (ELN) criteria, fails to detect the majority of patients with later disease progression and is paralleled by a smaller proportion of high-risk patients and less progressions identified by the 6-month landmark.
Journal ArticleDOI
Time-Related Interpretation of Molecular Response Levels According to Long Term Overall and Progression-Free Survival of CML Patients on First-Line Imatinib Treatment
Martin C. Müller,Benjamin Hanfstein,Michael Lauseker,Philipp Erben,Ulrike Proetel,Susanne Schnittger,Hans-Jochem Kolb,Stefan W. Krause,Christoph Nerl,Dominik Heim,Gabriela M. Baerlocher,Joerg E. A. Schubert,Hermann Einsele,M Hänel,Jolanta Dengler,Christiane Falge,Lothar Kanz,Andreas Neubauer,Michael Kneba,Frank Stegelmann,Michael Pfreundschuh,Cornelius F. Waller,Markus Pfirrmann,Jörg Hasford,Wolf-Karsten Hofmann,Rüdiger Hehlmann,Susanne Saussele,Andreas Hochhaus +27 more
TL;DR: Faster and deeper response to imatinib-based treatment revealed to be associated with improved overall and progression-free survival.